General Pharmacology Practice Questions

Q: High continuous doses of agonist drugs cause which of the following?

Down-regulation of receptors. **Explanation:** The correct answer is **A. Down-regulation of receptors.** This phenomenon is a classic example of **receptor regulation**, a homeostatic mechanism the body uses to maintain equilibrium. When a cell is exposed to high, continuous concentrations of an **agonist**, the receptors are overstimulated. To protect the cell from excessive activation, the body reduces the number or sensitivity of these receptors. This occurs through: 1. **Internalization:** Receptors are moved from the cell membrane into the cytoplasm via endocytosis. 2. **Degradation:** Receptors are broken down by lysosomes. 3. **Reduced Synthesis:** Decreased production of new receptor proteins. **Why the other options are incorrect:** * **B. Up-regulation of receptors:** This is the opposite process. It occurs in response to chronic exposure to **antagonists** (blockers) or due to denervation. When receptors are blocked, the cell compensates by increasing the number of receptors to catch any available signal. * **C. Depends on the dose:** While the *extent* of down-regulation is dose-dependent, the *direction* of the physiological response to a continuous agonist is consistently down-regulation. **High-Yield NEET-PG Pearls:** * **Tachyphylaxis:** A rapid form of desensitization (e.g., repeated doses of Ephedrine or Tyramine). * **Tolerance:** A gradual decrease in responsiveness to a drug (e.g., Morphine, Nitrates) often mediated by down-regulation. * **Clinical Consequence:** Sudden withdrawal of an antagonist (like Propranolol) can lead to "rebound hypertension" or angina because the receptors were **up-regulated** during treatment, making the cell hypersensitive to endogenous ligands.

Q: A drug that shifts the dose-response curve to the left has:

More potency. ### Explanation **1. Why "More Potency" is Correct:** Potency refers to the amount of drug (dose) required to produce a specific effect of a given intensity. On a graded dose-response curve (DRC), the x-axis represents the dose/concentration (usually in log scale). When a drug's DRC shifts to the **left**, it indicates that a **lower dose** is required to achieve the same response (e.g., the $ED_{50}$). Therefore, a leftward shift signifies higher potency. **2. Why Other Options are Incorrect:** * **Option A (More Efficacy):** Efficacy is the maximal response ($E_{max}$) a drug can produce. On a DRC, efficacy is represented by the **height (y-axis)** of the curve. A drug with more efficacy would have a taller curve, not necessarily a leftward shift. * **Option C (More Safety):** Safety is typically measured by the **Therapeutic Index** ($LD_{50}/ED_{50}$). A shift to the left only tells us about the drug's power at low doses; it does not provide information about the lethal dose or the margin of safety unless compared with the toxicity curve. **3. NEET-PG High-Yield Pearls:** * **Potency vs. Efficacy:** Efficacy is clinically more important than potency. For example, Furosemide is more efficacious than Chlorothiazide because it can remove more fluid, regardless of the milligram dose used. * **Competitive Antagonists:** These shift the DRC of an agonist to the **right** (increasing $ED_{50}$, decreasing potency) without affecting the maximal response (efficacy). * **Non-competitive Antagonists:** These shift the DRC **downwards**, decreasing the maximal response (efficacy) without necessarily changing the $ED_{50}$ (potency). * **$ED_{50}$ (Median Effective Dose):** The dose at which 50% of the maximal effect is observed. It is the standard measure used to compare the potency of drugs.

Q: Which of the following inhibits Cytochrome P450?

Cimetidine. The correct answer is **Cimetidine**. This question tests the fundamental pharmacological concept of microsomal enzyme modulation (Induction vs. Inhibition). **1. Why Cimetidine is Correct:** Cimetidine is a classic **Cytochrome P450 (CYP450) inhibitor**. It binds to the heme iron of the CYP450 enzyme system, reducing the metabolic activity of enzymes like CYP1A2, 2C9, and 2D6 [1]. This leads to decreased metabolism and increased plasma levels of co-administered drugs (e.g., Warfarin, Theophylline, Phenytoin), potentially causing toxicity [1]. **2. Analysis of Incorrect Options:** * **Phenobarbitone (A) and Phenytoin (C):** These are potent **Microsomal Enzyme Inducers** [2]. They increase the synthesis of CYP450 enzymes, leading to faster metabolism and reduced efficacy of other drugs (e.g., Oral Contraceptive Pills, leading to failure) [2]. * **Carbon tetrachloride (D):** This is a hepatotoxin. While it can damage the liver and eventually reduce metabolic capacity through cellular necrosis, it is not classified as a pharmacological "enzyme inhibitor" in the context of drug-drug interactions. **3. High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inhibitors (VITAMIN K):** **V**erapamil, **I**soniazid, **T**amoxifen, **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**etupitant, **K**etoconazole (and other Azoles), **C**imetidine, **C**iprofloxacin, **G**rapefruit juice. [2] * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. [2] **Key Fact:** Cimetidine also has anti-androgenic effects (can cause gynecomastia), a common side effect frequently asked in NEET-PG alongside its enzyme-inhibiting property.

Q: Which of the following statements about Mycophenolate Mofetil is not true?

Most common adverse effect is Nephrotoxicity. **Explanation:** **1. Why Option A is the correct (false) statement:** Mycophenolate Mofetil (MMF) is notably **not nephrotoxic**. This is a high-yield distinction because it is frequently used as a "calcineurin inhibitor-sparing agent" to reduce the dose of drugs like Cyclosporine or Tacrolimus, which are notoriously nephrotoxic. The most common adverse effects of MMF are **gastrointestinal (GI) disturbances** (nausea, vomiting, diarrhea, and abdominal pain) and **myelosuppression** (leukopenia). **2. Analysis of other options:** * **Option B:** MMF is a standard immunosuppressant used to prevent **acute and chronic transplant rejection** (kidney, heart, and liver) and in autoimmune conditions like Lupus Nephritis. * **Option C:** MMF is indeed a **prodrug**. After oral administration, it is rapidly hydrolyzed by esterases in the gut and liver to its active metabolite, **Mycophenolic Acid (MPA)**. * **Option D:** MMF and Azathioprine are both antimetabolites that inhibit purine synthesis. Using them together increases the risk of severe bone marrow suppression without significant therapeutic benefit; hence, they are **not used concurrently**. **Clinical Pearls for NEET-PG:** * **Mechanism of Action:** MMF is a selective, non-competitive, reversible inhibitor of **Inosine Monophosphate Dehydrogenase (IMPDH)**. This inhibits the *de novo* pathway of guanosine nucleotide synthesis. * **Selectivity:** Since T and B lymphocytes rely solely on the *de novo* pathway (unlike other cells that use the salvage pathway), MMF is highly selective for lymphocytes. * **Teratogenicity:** MMF is associated with "Mycophenolate embryopathy" (ear and facial abnormalities); it is contraindicated in pregnancy.

Q: Prostaglandin E2 analogs can be used for all of the following conditions EXCEPT:

Treatment of patent ductus arteriosus. The correct answer is **A. Treatment of patent ductus arteriosus**. [1] In fetal life, the ductus arteriosus is kept open by endogenous prostaglandins (PGE2). After birth, if the ductus remains open (Patent Ductus Arteriosus - PDA), it leads to abnormal hemodynamics [2]. To treat PDA, we aim to **close** the shunt by inhibiting prostaglandin synthesis using **NSAIDs** (e.g., Indomethacin or Ibuprofen). Conversely, PGE2 analogs (Alprostadil) are used to *maintain* patency in ductal-dependent congenital heart diseases, not to treat PDA [2]. **Analysis of other options:** * **B. Treatment of bronchial asthma:** While not a first-line agent, PGE2 has bronchodilatory properties. Note that PGF2$\alpha$ and PGD2 are bronchoconstrictors, but PGE2 acts as a vasodilator and bronchodilator. * **C. Cervical priming:** PGE2 analogs like **Dinoprostone** are gold-standard agents used for cervical ripening and induction of labor as they soften the cervix and stimulate uterine contractions [1], [4]. * **D. Treatment of NSAID-induced peptic ulcer:** **Misoprostol** (a PGE1/E2 analog) is cytoprotective [3]. It increases bicarbonate and mucus secretion while decreasing gastric acid production, making it the drug of choice for preventing NSAID-induced ulcers [1], [3]. **High-Yield Clinical Pearls for NEET-PG:** * **PGE1 Analog (Alprostadil):** Used for maintaining ductus patency and erectile dysfunction [1]. * **PGE1 Analog (Misoprostol):** Used for medical abortion (with Mifepristone) and NSAID-induced ulcers [1]. * **PGF2$\alpha$ Analogs (Latanoprost):** First-line for Glaucoma [1]. * **PGI2 Analogs (Epoprostenol):** Used in Pulmonary Hypertension [1].

Q: Good clinical practice (GCP) is seen in all of the following except?

Preclinical trials. **Explanation:** **Good Clinical Practice (GCP)** is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of **human subjects**. **Why Preclinical trials is the correct answer:** Preclinical trials involve experiments conducted in **in-vitro** (cell culture) and **in-vivo** (animal models) settings to assess safety and biological efficacy before a drug is tested in humans. Because these trials do not involve human participants, they are governed by **Good Laboratory Practice (GLP)** rather than GCP. **Why the other options are incorrect:** * **Phase I, II, and IV trials:** All phases of clinical trials (Phase I through IV) involve human volunteers or patients. Compliance with GCP is mandatory for these phases to ensure that the rights, safety, and well-being of trial subjects are protected (consistent with the Declaration of Helsinki) and that the clinical trial data are credible. **High-Yield Clinical Pearls for NEET-PG:** * **GLP (Good Laboratory Practice):** Applies to non-clinical safety studies (Preclinical trials). * **GMP (Good Manufacturing Practice):** Applies to the consistent production and quality control of pharmaceutical products. * **GCP Guidelines:** Developed by the **ICH** (International Council for Harmonisation). * **Schedule Y:** In the Indian context (Drugs and Cosmetics Act), Schedule Y formerly laid down the guidelines for clinical trials (now replaced by the New Drugs and Clinical Trial Rules, 2019). * **Nuremberg Code & Declaration of Helsinki:** These are the historical foundations upon which GCP guidelines were built.

Q: Therapeutic monitoring of plasma drug levels is indicated for all of the following drugs except:

Warfarin. **Explanation:** Therapeutic Drug Monitoring (TDM) is indicated for drugs with a **narrow therapeutic index**, where the plasma concentration correlates well with the clinical effect or toxicity, and where the pharmacological effect is difficult to measure directly. **Why Warfarin is the correct answer:** While Warfarin has a narrow therapeutic index, we do **not** monitor its plasma levels. Instead, we monitor its pharmacodynamic effect using the **Prothrombin Time (PT)** and **International Normalized Ratio (INR)**. TDM is unnecessary when a simple, reliable physiological marker (like INR) can directly reflect the drug's efficacy and risk of toxicity. **Analysis of incorrect options:** * **Gentamicin:** An aminoglycoside with significant nephrotoxicity and ototoxicity. TDM is essential to ensure efficacy while minimizing toxicity, especially monitoring "trough" levels. * **Cyclosporine:** An immunosuppressant with highly variable pharmacokinetics and a narrow window. Monitoring is mandatory to prevent graft rejection (if levels are low) and nephrotoxicity (if levels are high). * **Phenytoin:** Follows **zero-order (non-linear) kinetics** at therapeutic doses. Small dose increases can lead to disproportionately large increases in plasma concentration, making TDM vital to avoid neurotoxicity. **High-Yield Clinical Pearls for NEET-PG:** * **TDM is NOT required for:** Drugs with a wide therapeutic index (e.g., Penicillin), drugs whose effect is easily measured (e.g., Antihypertensives via BP, Warfarin via INR, Hypoglycemics via Blood Glucose), and "hit-and-run" drugs (e.g., Omeprazole). * **Common TDM Drugs:** Lithium, Digoxin, Theophylline, Vancomycin, Tricyclic Antidepressants (TCAs), and Antiepileptics (Phenytoin, Carbamazepine).

Q: Pharmacovigilance is done for monitoring what?

Drug safety. **Explanation:** **Pharmacovigilance (PV)** is defined by the WHO as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Its primary objective is to ensure **Drug Safety** (Option C) after a drug has been released into the market. * **Why Option C is correct:** Clinical trials (Phases I-III) are conducted on a limited number of selected patients. Rare adverse drug reactions (ADRs), long-term toxicity, or interactions may only surface when the drug is used by the general population. Pharmacovigilance (Phase IV/Post-marketing surveillance) monitors these real-world outcomes to protect patient health. * **Why Options A, B, and D are incorrect:** * **Drug price:** Monitored by regulatory bodies like the NPPA (National Pharmaceutical Pricing Authority), not PV. * **Unethical practices:** These are overseen by Ethics Committees and bodies like the NMC (National Medical Commission). * **Pharmacology students:** PV is a scientific discipline, not a student monitoring system. **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the WHO's international database for ADR reporting. * **Methods:** Spontaneous reporting is the most common method used in PV. * **Goal:** To identify "signals" (new information on a known ADR or a previously unknown ADR).

Q: Which of the following reactions is NOT catalyzed by microsomal enzymes?

Acetylation. Drug metabolism is divided into Phase I (Functionalization) and Phase II (Conjugation) reactions. These are catalyzed by enzymes located either in the **microsomes** (smooth endoplasmic reticulum) or the **cytoplasm/mitochondria** (non-microsomal). **Why Acetylation is the correct answer:** Acetylation is a Phase II conjugation reaction catalyzed by the enzyme **N-acetyltransferase (NAT)**. Unlike most other conjugation reactions, NAT is a **non-microsomal enzyme** located in the cytoplasm of hepatocytes and other tissues [1]. Therefore, it does not require the microsomal cytochrome P450 system. **Analysis of Incorrect Options:** * **Glucuronidation (Option A):** This is the **only** Phase II reaction catalyzed by microsomal enzymes (specifically UDP-glucuronosyltransferases or UGTs) [1, 2]. It is the most common conjugation pathway. * **Oxidation (Option B):** Most Phase I oxidative reactions (e.g., hydroxylation, dealkylation) are catalyzed by the microsomal **Cytochrome P450** monooxygenase system [1]. * **Reduction (Option C):** Many reductive reactions (e.g., chloramphenicol metabolism) are carried out by microsomal enzymes, though some can occur non-microsomally. **High-Yield NEET-PG Pearls:** 1. **Phase II Rule:** All Phase II reactions are non-microsomal **EXCEPT** Glucuronidation. 2. **Phase I Rule:** Most Phase I reactions are microsomal **EXCEPT** those involving Alcohol Dehydrogenase (cytosol), MAO (mitochondria), and Xanthine Oxidase. 3. **Acetylation Polymorphism:** This is clinically significant for drugs like **Isoniazid, Hydralazine, and Procainamide** (Mnemonic: **SHIP** - Sulfonamides, Hydralazine, Isoniazid, Procainamide). "Slow acetylators" are at higher risk of toxicity (e.g., peripheral neuropathy with Isoniazid or SLE with Hydralazine). 4. **Microsomal Induction:** Microsomal enzymes are inducible by drugs like Phenobarbitone and Rifampicin, whereas non-microsomal enzymes are generally non-inducible.

Question 1

High continuous doses of agonist drugs cause which of the following?

Accepted Answer

Down-regulation of receptors

Answer

Up-regulation of receptors

Answer

Depends on the dose

Answer

None of the above

Question 2

A drug that shifts the dose-response curve to the left has:

Accepted Answer

More potency

Answer

More efficacy

Answer

More safety

Answer

None of the above

Question 3

Which of the following inhibits Cytochrome P450?

Accepted Answer

Cimetidine

Answer

Phenobarbitone

Answer

Phenytoin

Answer

Carbon tetrachloride

Question 4

Which of the following statements about Mycophenolate Mofetil is not true?

Accepted Answer

Most common adverse effect is Nephrotoxicity

Answer

Used in Transplant Rejection

Answer

It is a prodrug and converted to Mycophenolic acid

Answer

Is not used with Azathioprine

Question 5

Prostaglandin E2 analogs can be used for all of the following conditions EXCEPT:

Accepted Answer

Treatment of patent ductus arteriosus

Answer

Treatment of bronchial asthma

Answer

Cervical priming

Answer

Treatment of NSAID-induced peptic ulcer

Question 6

Good clinical practice (GCP) is seen in all of the following except?

Accepted Answer

Preclinical trials

Answer

Phase I trials

Answer

Phase II trials

Answer

Phase IV trials

Question 7

Which of the following antibiotics accentuates the neuromuscular blockade produced by pancuronium?

Accepted Answer

Streptomycin

Answer

Erythromycin

Answer

Penicillin G

Answer

Chloramphenicol

Question 8

Therapeutic monitoring of plasma drug levels is indicated for all of the following drugs except:

Accepted Answer

Warfarin

Answer

Gentamicin

Answer

Cyclosporine

Answer

Phenytoin

Question 9

Pharmacovigilance is done for monitoring what?

Accepted Answer

Drug safety

Answer

Drug price

Answer

Unethical practices

Answer

Pharmacology students

Question 10

Which of the following reactions is NOT catalyzed by microsomal enzymes?

Accepted Answer

Acetylation

Answer

Glucuronidation

Answer

Oxidation

Answer

Reduction

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?